Compugen Investor Relations Material

Compugen Ltd. is a clinical-stage therapeutic discovery and development company that focuses on immuno-oncology and autoimmune diseases. The company leverages a predictive computational discovery platform to identify novel drug targets and develop therapeutic products. Its pipeline includes a range of products in clinical trials, such as COM701 and COM902, which target various cancers including non-small cell lung cancer and head and neck squamous cell carcinoma. The company is headquartered in Holon, Israel, and its shares are listed on the NASDAQ.